Stock AnalizLiquidia Corp LQDA
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Liquidia Corp (LQDA) is a healthcare company listed in the US with a market value of about $5.2B. In the twelve months to September 30, 2026 it had revenue of $622M and net income of -$94M, a net margin of -15.1%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (1/5).
Key numbers: a price to free cash flow of 17.8, 5-year revenue growth of 192% a year, a 5-year average ROIC of -75%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.
Score: 2.2 / 5
Checks passed
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $622M | $158M | $14M | $17M | $16M | $13M | $739628 | $8M |
| Net income | -$94M | -$69M | -$128M | -$79M | -$41M | -$35M | -$60M | -$48M |
| Free cash flow | $291M | -$40M | -$98M | -$43M | -$29M | -$34M | -$55M | -$50M |
| EPS (diluted) | $-1.05 | $-0.80 | $-1.63 | $-1.21 | $-0.67 | $-0.70 | $-1.76 | $-2.57 |
| Net margin | -15.1% | -43.5% | -916.6% | -448.9% | -257.4% | -269.0% | -8080.1% | -589.5% |
| ROIC | — | -90.7% | -111.0% | -114.5% | -26.7% | -33.1% | -53.6% | -64.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $63.88, 11% above the current price; targets range from $33.00 to $87.00; the consensus rating is “Buy”; expected EPS is $0.07 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Liquidia stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Liquidia pay a dividend?
Not currently.
Is Liquidia a good stock to buy?
We do not give buy or sell advice. Liquidia scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.